Results 1 to 10 of about 37,664 (239)

Identification of potent biparatopic antibodies targeting FGFR2 fusion–driven cholangiocarcinoma

The Journal of Clinical Investigation
Translocations involving FGFR2 gene fusions are common in cholangiocarcinoma and predict response to FGFR kinase inhibitors. However, response rates and durability are limited due to the emergence of resistance, typically involving FGFR2 kinase domain ...
Saireudee Chaturantabut, Sydney Oliver, Dennie T. Frederick, Jiwan J. Kim, Foxy P. Robinson, Alessandro Sinopoli, Tian-Yu Song, Yao He, Yuan-Chen Chang, Diego J. Rodriguez, Liang Chang, Devishi Kesar, Meilani Ching, Ruvimbo Dzvurumi, Adel Atari, Yuen-Yi Tseng, Nabeel Bardeesy, William R. Sellers   +17 more
doaj   +1 more source

Early‐Onset Gastric Cancer as a High‐Risk Disease Entity in the United States: Clinicopathologic Features, Regional Variation, and Outcomes

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Introduction Early‐onset gastric cancer (EOGC), defined as diagnosis before age 45, represents a distinct and increasingly recognized subset of gastric cancer. Emerging evidence suggests that clinical behavior, treatment patterns, and outcomes differ from average‐onset disease, yet these differences remain incompletely characterized.
Dani R. Castillo, Pranati Shah, Derek Tai, Mengni Guo, Max Hazeltine, Sofia Guzman, Daniel Park, Rifat Mannan, Yan Xing, Gagandeep Brar, Mustafa Raoof, Cathy Eng, Shengyang Wu   +12 more
wiley   +1 more source

Human Epidermal Growth Factor Receptor 2‐Positive, Claudin‐18 Isoform 2‐Positive, Mismatch Repair‐Deficient Gastric Cancer Revealed by Immunohistochemical Analysis of Surgical Specimens: A Case Report

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Human epidermal growth factor receptor 2 (HER2), mismatch repair (MMR) proteins, claudin‐18 isoform 2 (CLDN18.2), and the programmed cell death ligand‐1 combined positive score (PD‐L1 CPS) are predictive biomarkers for the efficacy of combination chemotherapy in patients with locally advanced unresectable or metastatic gastric or ...
Daichi Takagi, Mikito Mori, Kiyohiko Shuto, Chihiro Kosugi, Akihiro Usui, Ryosuke Takayanagi, Shunsuke Sato, Sumiyo Adachi, Takashi Fujino, Kazuto Yamazaki, Hiroaki Shimizu   +10 more
wiley   +1 more source

Obstructive Sleep Apnea: Epidemiology, Pathophysiology, Complications, Diagnosis, Management, and Emerging Fibrosis‐Linked Remodeling

MedComm, Volume 7, Issue 8, August 2026.
Obstructive sleep apnea (OSA) is characterized by recurrent upper‐airway collapse, which generates key nocturnal stressors including intermittent hypoxia, sleep fragmentation, intrathoracic pressure stress, and sympathetic activation. These physiological disturbances converge on shared biological mechanisms, including oxidative stress, inflammation ...
Nhi Ho Thi Thuy, Thị Hằng Giang Phan, Ali Hussein Eid, Paola Maccioccu, Stefania Camboni, Gavino Casu, Anna Maria Posadino, Roberta Giordo, Gianfranco Pintus   +8 more
wiley   +1 more source

Application of Systems Genetics to Investigate Molecular Pathology of Early‐Onset Colorectal Cancer

Chemical Biology &Drug Design, Volume 108, Issue 2, August 2026.
Early‐onset colorectal cancer (EOCRC) presents a complex molecular landscape that requires integrated multi‐omics approaches. This article reviews current applications of systems genetics in EOCRC research and provides a step‐by‐step protocol for network‐based analyses featuring PIK3CA to demonstrate practical application for researchers of all levels.
Minjae J. Kim, Sydney L. Carr, Vishnutheertha Kulkarni, Mary‐Louise Manchadi   +3 more
wiley   +1 more source

Genomic complexity in advanced gastric and esophageal adenocarcinomas: a case report of rare WDR11-AS1-FGFR2 fusions

Frontiers in Oncology
Fibroblast growth factor receptor 2 (FGFR2) alterations represent an emerging therapeutic target in gastroesophageal adenocarcinoma (GEA). Although FGFR2 amplifications and overexpression have been associated with poor prognosis and therapeutic ...
Eric Mehlhaff, Dustin A. Deming, Dustin A. Deming, Jeremy D. Kratz, Jeremy D. Kratz, Jeremy D. Kratz, Khaldun Obeidat, Lauren Welch, Nataliya Uboha, Nataliya Uboha   +9 more
doaj   +1 more source

Molecular Characterization of Ovarian Yolk Sac Tumor in a Postmenopausal Woman: Implications for Pathogenesis

Journal of Obstetrics and Gynaecology Research, Volume 52, Issue 8, August 2026.
ABSTRACT Ovarian yolk sac tumor is a rare malignant germ cell tumor that typically occurs in young women. In postmenopausal women, yolk sac tumors are extremely rare and have a poor prognosis. These tumors may arise from different biological mechanisms, as germ cells are absent in postmenopausal ovaries.
Mihiro Dejima, Minoru Nagashima, Mamiko Onuki, Miki Kushima, Akihiko Sekizawa, Koji Matsumoto   +5 more
wiley   +1 more source

Prognostic Impact of Concomitant Genomic Alterations in FGFR2‐Positive Cholangiocarcinoma Treated With Pemigatinib

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Background & Aims Anti‐FGFR therapies changed the treatment landscape for patients with previously treated, advanced, or metastatic cholangiocarcinoma (CCA) harbouring FGFR2 fusions/rearrangements. However, primary resistance to FGFR inhibitors remains a key challenge. In the present real‐world study, we aimed to evaluate the prognostic impact
Carolina Liguori, Riccardo Giampieri, Blandine Delaunay, Giada Pinterpe, Adelaide Mazzocca, Antoine Hollebecque, Jean Frederic Blanc, Mohamed Bouattour, Eric Assenat, Meher Ben Abdelghani, Matthieu Sarabi, Monica Niger, Caterina Vivaldi, Mario Mandalà, Andrea Palloni, Maria Bensi, Silvio Ken Garattini, David Tougeron, Pierre Combe, Massimiliano Salati, Margherita Rimini, Andrea Casadei‐Gardini, Chiara Alessandra Cella, Marco Tucci, Anna Diana, Elena Mori, Raffaella Longarini, Pascal Artru, Gael Roth, Ludovic Evesque, Agathe Vienne, Anthony Turpin, Sandrine Hiret, Vincent Bourgeois, Camille Herve, Rodolphe Paulon, Marion Stacoffe, David Malka, Matthieu Delaye, Julien Edeline, Astrid Lievre, Rosine Guimbaud, Rita Balsano, Nadim Fares, Rossana Berardi, Alessandro Parisi   +45 more
wiley   +1 more source

Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary

Molecular Therapy
Patients with cancer of unknown primary (CUP) carry the double burden of an aggressive disease and reduced access to therapies. Experimental models are pivotal for CUP biology investigation and drug testing. We derived two CUP cell lines (CUP#55 and #96) and corresponding patient-derived xenografts (PDXs), from ascites tumor cells.
Cavazzoni A., Salamon I., Fumarola C., Gallerani G., Laprovitera N., Gelsomino F., Riefolo M., Rihawi K., Porcellini E., Rossi T., Mazzeschi M., Naddeo M., Serravalle S., Broseghini E., Agostinis F., Deas O., Roncarati R., Durante G., Pace I., Lauriola M., Garajova I., Calin G. A., Bonafe M., D'Errico A., Petronini P. G., Cairo S., Ardizzoni A., Sales G., Ferracin M.   +28 more
openaire   +7 more sources

Síndrome de Apert, una aproximación para un diagnóstico clínico. Reporte de caso

Salud Uninorte, 2010
Introducción: El síndrome de Apert, o acrocefalosindactilia tipo I, es un síndrome caracterizado por craneosinostosis, acompañada de sindactilia simétrica en las cuatro extremidades, alteraciones maxilofaciales, cutáneas y retardo mental variable.
Diana Ramírez, Wilmar Saldarriaga, Harry Pachajoa, Carolina Isaza   +3 more
doaj